[HTML][HTML] Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody
M Tré-Hardy, A Wilmet, I Beukinga… - Clinical Chemistry and …, 2020 - degruyter.com
Objectives Faced with the COVID-19 pandemic and its impact on the availability and quality
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody
M Tré-Hardy, A Wilmet, I Beukinga… - Clinical chemistry …, 2020 - pubmed.ncbi.nlm.nih.gov
Objectives Faced with the COVID-19 pandemic and its impact on the availability and quality
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody.
M Tré-Hardy, A Wilmet, I Beukinga… - Clinical Chemistry & …, 2020 - search.ebscohost.com
Objectives: Faced with the COVID-19 pandemic and its impact on the availability and quality
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
[PDF][PDF] Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody
M Tré-Hardy, A Wilmet, I Beukinga, JM Dogné… - pure.unamur.be
Objectives: Faced with the COVID-19 pandemic and its impact on the availability and quality
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody.
M Tré-Hardy, A Wilmet, I Beukinga… - Clinical Chemistry …, 2020 - europepmc.org
Objectives Faced with the COVID-19 pandemic and its impact on the availability and quality
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
[PDF][PDF] Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody
M Tré-Hardy, A Wilmet, I Beukinga, JM Dogné… - Clin Chem Lab …, 2020 - dipot.ulb.ac.be
Objectives: Faced with the COVID-19 pandemic and its impact on the availability and quality
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
[HTML][HTML] Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody
M Tré-Hardy, A Wilmet, I Beukinga… - Clinical Chemistry and …, 2020 - degruyter.com
Objectives Faced with the COVID-19 pandemic and its impact on the availability and quality
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody.
M Tré-Hardy, A Wilmet, I Beukinga, L Blairon… - 2020 - cabidigitallibrary.org
Objectives: Faced with the COVID-19 pandemic and its impact on the availability and quality
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch …
Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody
M Tré-Hardy, A Wilmet, I Beukinga… - Clinical Chemistry …, 2020 - researchportal.unamur.be
Faced with the COVID-19 pandemic and its impact on the availability and quality of both
therapeutic and diagnostic methods, the Belgian authorities have decided to launch a …
therapeutic and diagnostic methods, the Belgian authorities have decided to launch a …
[引用][C] Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody
M Tré-Hardy, A Wilmet, I Beukinga… - Clinical chemistry …, 2020 - difusion.ulb.ac.be